Dozens of these buttons flooded the United States Food and Drug Administration’s (FDA) headquarters at a meeting for the widely prescribed asthma/allergy medication, montelukast (brand name, Singulair).  The message was simple: “The benefits did not outweigh the risks.” As each button approached the podium, the panel of experts heard gut-wrenching testimonials about the unimaginable psychiatric […]